BioCentury
ARTICLE | Clinical News

REP 2165-Mg: Phase IIb started

October 12, 2015 7:00 AM UTC

Replicor began the open-label, Moldovan Phase IIb REP 401 trial of REP 2139-Mg or REP 2165-Mg in about 60 Caucasian patients who have received Viread tenofovir disoproxil fumarate for 24 weeks. All ...